Annual accounts receivable:
$8.52M-$27.94M(-76.64%)Summary
- As of today (July 27, 2025), NTLA annual accounts receivable is $8.52 million, with the most recent change of -$27.94 million (-76.64%) on December 31, 2024.
- During the last 3 years, NTLA annual accounts receivable has risen by +$6.49 million (+319.35%).
- NTLA annual accounts receivable is now -76.64% below its all-time high of $36.46 million, reached on December 31, 2023.
Performance
NTLA Accounts receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly accounts receivable:
$10.50M+$1.99M(+23.33%)Summary
- As of today (July 27, 2025), NTLA quarterly accounts receivable is $10.50 million, with the most recent change of +$1.99 million (+23.33%) on March 31, 2025.
- Over the past year, NTLA quarterly accounts receivable has dropped by -$25.92 million (-71.16%).
- NTLA quarterly accounts receivable is now -71.19% below its all-time high of $36.46 million, reached on December 31, 2023.
Performance
NTLA Quarterly accounts receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Accounts receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
NTLA Accounts receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -76.6% | -71.2% |
| 3 y3 years | +319.4% | +483.2% |
| 5 y5 years | +84.3% | -21.4% |
NTLA Accounts receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -76.6% | +319.4% | -71.2% | +268.0% |
| 5 y | 5-year | -76.6% | +319.4% | -71.2% | +1002.2% |
| alltime | all time | -76.6% | >+9999.0% | -71.2% | +1002.2% |
NTLA Accounts receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $10.50M(+23.3%) |
| Dec 2024 | $8.52M(-76.6%) | $8.52M(-3.8%) |
| Sep 2024 | - | $8.85M(-28.2%) |
| Jun 2024 | - | $12.33M(-66.2%) |
| Mar 2024 | - | $36.43M(-0.1%) |
| Dec 2023 | $36.46M(+867.5%) | $36.46M(+461.6%) |
| Sep 2023 | - | $6.49M(+28.4%) |
| Jun 2023 | - | $5.06M(+3.1%) |
| Mar 2023 | - | $4.91M(+30.2%) |
| Dec 2022 | $3.77M(+85.5%) | $3.77M(-6.3%) |
| Sep 2022 | - | $4.02M(+41.0%) |
| Jun 2022 | - | $2.85M(+58.5%) |
| Mar 2022 | - | $1.80M(-11.3%) |
| Dec 2021 | $2.03M(-4.6%) | $2.03M(-18.5%) |
| Sep 2021 | - | $2.49M(+25.0%) |
| Jun 2021 | - | $1.99M(+109.1%) |
| Mar 2021 | - | $953.00K(-55.3%) |
| Dec 2020 | $2.13M | $2.13M(+75.0%) |
| Sep 2020 | - | $1.22M(-68.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2020 | - | $3.86M(-71.1%) |
| Mar 2020 | - | $13.37M(+189.4%) |
| Dec 2019 | $4.62M(-38.8%) | $4.62M(+28.4%) |
| Sep 2019 | - | $3.60M(-14.1%) |
| Jun 2019 | - | $4.19M(+16.6%) |
| Mar 2019 | - | $3.59M(-52.4%) |
| Dec 2018 | $7.55M(-27.9%) | $7.55M(+168.3%) |
| Sep 2018 | - | $2.81M(-67.3%) |
| Jun 2018 | - | $8.61M(+15.3%) |
| Mar 2018 | - | $7.47M(-28.7%) |
| Dec 2017 | $10.47M(+62.2%) | $10.47M(+133.1%) |
| Sep 2017 | - | $4.49M(+62.6%) |
| Jun 2017 | - | $2.76M(+13.1%) |
| Mar 2017 | - | $2.44M(-62.1%) |
| Dec 2016 | $6.45M(+545.4%) | $6.45M(+480.4%) |
| Sep 2016 | - | $1.11M(+11.2%) |
| Jun 2016 | - | $1.00M(0.0%) |
| Mar 2016 | - | $1.00M(0.0%) |
| Dec 2015 | $1.00M(>+9900.0%) | $1.00M |
| Dec 2014 | $0.00 | - |
FAQ
- What is Intellia Therapeutics, Inc. annual accounts receivable?
- What is the all time high annual accounts receivable for Intellia Therapeutics, Inc.?
- What is Intellia Therapeutics, Inc. annual accounts receivable year-on-year change?
- What is Intellia Therapeutics, Inc. quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Intellia Therapeutics, Inc.?
- What is Intellia Therapeutics, Inc. quarterly accounts receivable year-on-year change?
What is Intellia Therapeutics, Inc. annual accounts receivable?
The current annual accounts receivable of NTLA is $8.52M
What is the all time high annual accounts receivable for Intellia Therapeutics, Inc.?
Intellia Therapeutics, Inc. all-time high annual accounts receivable is $36.46M
What is Intellia Therapeutics, Inc. annual accounts receivable year-on-year change?
Over the past year, NTLA annual accounts receivable has changed by -$27.94M (-76.64%)
What is Intellia Therapeutics, Inc. quarterly accounts receivable?
The current quarterly accounts receivable of NTLA is $10.50M
What is the all time high quarterly accounts receivable for Intellia Therapeutics, Inc.?
Intellia Therapeutics, Inc. all-time high quarterly accounts receivable is $36.46M
What is Intellia Therapeutics, Inc. quarterly accounts receivable year-on-year change?
Over the past year, NTLA quarterly accounts receivable has changed by -$25.92M (-71.16%)